false
0001739174
0001739174
2026-06-26
2026-06-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 26, 2026
BIOMX
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38762
|
|
82-3364020
|
(State
or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
850
New Burton Road, Suite 201
Dover,
Delaware 19904
(Address
of principal executive offices, including zip code)
(972)
52-437-4900
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.0001 par value per share |
|
PHGE |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07. Submission of Matters to a Vote of Security Holders.
BiomX
Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 26, 2026 in
a virtual meeting format. As of June 2, 2026, the record date for the Annual Meeting, there were 11,160,153 shares of the Company’s common
stock, par value $0.0001 per share, outstanding and entitled to vote. A total of 4,518,349 shares were represented in person (virtually)
or by proxy at the Annual Meeting, representing approximately 40.5% of the shares entitled to vote and constituting a quorum.
The vote results detailed below represent the final results as certified by the Inspector of Elections. The number of votes cast for,
against or withheld, as well as the number of abstentions and broker non-votes as to each proposal are set forth below.
Proposal
1: Election of Directors.
The
Company’s stockholders elected Ran Shaked, the Company’s sole Class III director nominee, to serve until the 2029 Annual Meeting of Stockholders
and until his successor has been duly elected and qualified. The voting results were as follows:
| Nominee | |
For | | |
Withheld | | |
Broker
Non-Votes | |
| Ran Shaked | |
| 5,120,627 | | |
| 39,796 | | |
| 0 | |
Proposal
2: Approval of an Amendment to the BiomX Inc. 2026 Equity Incentive Plan.
The
Company’s stockholders approved an amendment to the BiomX Inc. 2026 Equity Incentive Plan to increase the number of shares of common
stock reserved and available for issuance thereunder by 5,460,000 shares, to 6,850,000 shares from 1,390,000 shares. The voting results
were as follows:
| For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
| 4,351,470 |
|
775,111 |
|
33,842 |
|
0 |
Proposal
3: Adjournment Proposal.
The
Company’s stockholders approved the proposal to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there were
insufficient votes at the time of the Annual Meeting to approve one or more of the foregoing proposals. The voting results were as follows:
| For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
| 4,462,767 |
|
667,020 |
|
30,636 |
|
0 |
Because
Proposals 1 and 2 received sufficient votes for approval, no adjournment of the Annual Meeting was necessary.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BiomX
Inc.
Date:
June 26, 2026
| By: |
/s/ Michael Oster |
|
| Name: |
Michael Oster |
|
| Title: |
Chief Executive Officer |
|
2